Fig. 7.

Kinetics of the immune response for the mid-low dose of PER.C6®-based Sabin IPV (sIPV) and commercial reference Salk IPV (cIPV) and sIPV up to week 20 after vaccination. Cynomolgus monkeys were immunized at week 0, 3, 6 and 17 with the indicated vaccines. Sera were collected and virus neutralizing antibody titers for Salk were measured prior to each immunization and at week 9 and 20 after start of the study. The mean (+/− SD) titration endpoint per group (n = 6) is presented as a reciprocal of the titer. The dotted line is the cut-off for seroprotection in humans (serum dilution of 1:8). Footnote: reference cIPV = Imovax, Sanofi; reference sIPV = commercial sIPV, Kunming.